Abstract
Betamethasone (BTS) is used to treat chronic inflammatory skin disorders such as psoriasis and atopic dermatitis. Several nanostructure systems for cutaneous administration are being developed to improve drug release and permeability, reduce dose and administration frequency, and even avoid toxicity. This review summarizes the latest betamethasone nano-based drug delivery systems for chronic inflammatory skin disorders and explains challenges related to the formulation development, the preclinical, clinical, and regulatory approval. A scoping review was conducted by searching electronic databases, including PubMed, Scopus, and Web of Science, to identify studies published until June 2024. Of the 1081 articles found, 23 met the inclusion criteria. This review explores various colloidal formulations including polymeric, lipid, and supramolecular hydrogel nanostructure systems aimed at achieving localized anti-inflammatory effects. Hear we also discussed aspects related to toxicology, permeation, and areas lacking information for potential human use. BTS nano-based formulations are promising candidates for treating inflammatory skin disorders. However, further preclinical tests are still required, as none of the formulations have been subjected to clinical studies yet.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
